martindale.com
Legal Library
|
FDA's New Transparency Task Force: Mission and Opportunity for Public Comment by Edward M. Basile
King & Spalding LLP - Washington Office
Jennifer L. Bragg
King & Spalding LLP - Washington Office
Daniel Francis Donovan
King & Spalding LLP - Washington Office
Beverly Lorell
King & Spalding LLP - Atlanta Office
|
|
June 26, 2009
Previously published on June 12, 2009
On June 3, the U.S. Food and Drug Administration (FDA or Agency) announced the formation of the FDA Transparency Task Force (Task Force) to solicit public comments and to promulgate recommendations for enhancing the transparency of the FDA's internal activities and decision-making.
|
The views expressed in this document are solely the views of the author and not Martindale-Hubbell. This document is intended for informational purposes only and is not legal advice or a substitute for consultation with a licensed legal professional in a particular case or circumstance. |
| | View More Library Documents By... | | | |
| | | | King & Spalding LLP Overview |
Practice Area Resource Centers
|
|